期刊文献+

MUC1表达与食管癌细胞对紫杉醇及顺铂反应的关系 被引量:2

Relationship between MUC1Expression and the Response of Esophageal Carcinoma Cells to Cisplatin and Paclitaxel
暂未订购
导出
摘要 目的:探讨MUC1过表达与食管癌细胞对紫杉醇及顺铂反应的关系。方法:构建MUC1过表达的食管癌细胞株,建立食管癌细胞裸鼠移植瘤模型;然后,对成瘤裸鼠腹腔注射顺铂(8μg/kg,d1、d7)及紫杉醇(20μg/kg,d1、d7)。每3 d测量肿瘤体积及裸鼠体质量,绘制肿瘤生长曲线及裸鼠体质量曲线;测量肿瘤的终末体积,计算肿瘤抑瘤率;采用免疫组化方法检测化疗药物对肿瘤中Bcl-2及Ki-67表达的影响。结果:顺铂与紫杉醇都能抑制MUC1过表达的食管癌移植瘤的肿瘤体积及裸鼠体质量增加,与空载组相比差异有统计学意义(P<0.05),但顺铂与紫杉醇之间差异无统计学意义(P>0.05);顺铂和紫杉醇对MUC1沉默的食管癌移植瘤的抑制效应不明显;顺铂与紫杉醇能够明显下调MUC1过表达的移植瘤中Ki67的表达(P<0.01),上调Bcl-2的表达(P<0.01)。结论:顺铂与紫杉醇都能明显抑制MUC1过表达的食管癌移植瘤的生长及细胞增殖,促进细胞凋亡,顺铂的抑制效应与紫杉醇无明显差异,但顺铂对裸鼠体质量的影响较明显。 Objective:To investigate the relationship between MUC1 overexpression and response of esophageal cancer to pacli taxel and cisplatin. Methods: MUCl-overexpressed esophageal cancer cell lines were constructed and esophageal cancer cells xenograft models in nude mice were established. Cisplatin (8 μg/kg, dl, d7) and paclitaxel (20 μg/kg, dl, d7) were injected intraperitoneally. Tumor volumes and weights of nude mice were measured every three days, and tumor growth curves and body weight curves were drawn. The terminal tumor volumes were measured and tumor inhibition rates were calculated. Effect of the chemotherapeutic drugs on the expression of Bcl 2 and Ki-67 in tumor cells were detected by immunohistochemistry. Re- suits: Cisplatin and paclitaxel could suppress tumor growth of MUC1 overexpressed esophageal cancer. The weights of nude mice and tumor volumes in cisplatin group and paclitaxel group were less than those in no-load group, and the differences were statistically significant (P〈0. 05), but no obvious difference was found between cisplatin group and paclitaxel group (P〉 0.05). Meanwhile, significant inhibitory effect was not observed in stable MUCl-silenced esophageal cancer in nude mice. Cis- platin and paelitaxel could up-regulate the expression of Bcl 2 (P〈 0. 01), but down regulate the expression of Ki-67 (P 〈0.01). Conclusions: Cisplatin and paclitaxel can suppress the growth and proliferation but promote the apoptosis of MUC1 overexpressed esophageal cancer cells. The inhibitory effect has no obvious difference between cisplatin and paclitaxel (P〉 0.05), but cisplatin can obviously affect the weights of nude mice.
出处 《中国临床医学》 2014年第1期1-4,共4页 Chinese Journal of Clinical Medicine
基金 上海市科学技术委员会基金项目资助(编号:11140903603)
关键词 食管癌 MUC1 紫杉醇 顺铂 Esophageal cancer MUC1 Cisplatin Paclitaxel
  • 相关文献

参考文献6

  • 1王立顺,朱迅.MUC1和MUC2 mRNA在不同肿瘤组织的表达及其意义[J].中国肿瘤临床,2000,27(4):258-261. 被引量:29
  • 2Creaney J, Segal A, Sterrett G, et al. Overexpression and al- tered glyeosylation of MUCI in malignant mesothelioma [J]. Br J Cancer, 2008, 98(9): 1562-1569.
  • 3Chou TC. Theoretical basis, experimental design, and corn puterized simulation of synergism and antagonism in drug com- bination studies [J]. Pharmacol Rev, 2006, 58(3): 621 681.
  • 4苏翔宇,李苏宜,刘琳.奈达铂联合顺铂对人食管癌细胞株(Eca-109)抑制作用机制的研究[J].实用肿瘤杂志,2010,25(2):150-155. 被引量:3
  • 5Pathann, Aime-sempe C, Kitadass, et al. Microtubule-targe ring drugs induce bel 2 phosphorylation and association with pin1[J]. Neoplasia, 2001, 3(6) :550-559.
  • 6Forster K, obermeier A, Mitina O, et al. Role of p21(WAF1/ CIP1) as an attenuator of both proliferative and drug-induced apoptolie signals in BCR-ABI.- :rans{ormed hematopoielic cells [J].. Ann Hematol, 2008, 87(3) : 183 -193.

二级参考文献19

  • 1杨凌,边月红,黄淑红,黄敬爱,翟永华,谢经武,张红卫.CyclinB1、Cdk1、PCNA和Ki-67在食管癌组织中的表达[J].山东大学学报(理学版),2006,41(4):155-157. 被引量:3
  • 2McKian KP, Miller RC, Cassivi SD, et al. Curing patients with locally advanced esophageal cancer: an update on mulimodality therapy [ J ]. Dis Esophagus, 2006,19 (6) : 448 - 453.
  • 3Osaka Y, Takagi Y, Hoshino S, et al. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting [ J ]. Dis Esophagus,2006,19 (6) :473 - 476.
  • 4Yoshioka T, Gamoh M, Shineha R, et al. A new combination chemotherapy with cis-diammine- glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers [J]. Intern Med, 1999,38 ( 11 ) : 844 - 848.
  • 5Hirata S, Yatsuyanagi E, Yamazaki H, et al. Neoadjuvant chemotherapy for esophageal cancer by administration of nedaplatin alone [ J ]. Gan To Kagaku Ryoho, 2000,27 (2) :221 -226.
  • 6Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies [ J ]. Pharmacol Rev, 2007,59 (1) :621 -681.
  • 7Lee DH, Kim HT, Han JY, et al. A phase Ⅱ trial of rood/fled weekly irinoteean and cisplatin for chemotherapy-na? ve patients with metastatic or recurrent squamous cell carcinoma of the esophagus [ J ]. Cancer Chemother Pharmacol,2008,61 ( 1 ) :83 - 88.
  • 8Yoshioka T, Sakayori M, Kato S, et al. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation [ J ]. Int J Ciin Oncol,2006, 11 (6) : 454 - 460.
  • 9Sculler JP, Lafitte JJ, Paesmans M, et al. Phase Ⅲ randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage Ⅳ non- small-cell lung cancer [ J ]. Br J Cancer, 2000,83 (9) : 1128 - 1135.
  • 10Hirsch FR, Osterlind K, Jeppesen N, et al. Superiority of high-dose platinum ( cisplatin and earboplatin ) compared to earboplatin alone in combination chemotherapy for small-cell lung carcinoma: A prospective randomised trial of 280 consecutive patients [ J ]. Ann Oncol,2001,12 ( 5 ) :647 - 653.

共引文献29

同被引文献28

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部